SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech for less than cash value
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: AuBug who wrote (158)12/11/2002 5:58:52 PM
From: Hank  Read Replies (1) of 684
 
I'm not an expert on phage display but I would think that antibodies displayed on the surface of a phage wouldn't necessarily have the same binding affinity or in vivo efficacy for the target protein as one produced in a mouse due to differences in post translational modification. One of the main issues with using hMab's as a therapeutic agent is the potential for an immune response from the patient in response to these agents. For that reason, the in vivo activity of potential hMab's under development is always looked at closely in animal models, with mice being used most often. The rational is that if you produce the hMab in mice, then you will be less likely to produce an antibody that exhibits poor selectivity in vivo and/or elicits an autoimmune response. As I understand it, that's why many of the drug companies are using the ABGX approach. If you know something different, then I'd be interested in hearing your agruments.

Of course, if Genentech wins it's campaign to win a patent for all transgenically produced hMab's, the big drug companies will have to pay a royalty. That means they will probably not be as gung ho on using this approach in the future as they are now. That is really the major pitfall in buying companies like ABGX as far as I am concerned.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News